Peptides & Bloodwork: What to Test Before and After a Cycle

Disclaimer upfront: Many peptides discussed here (BPC-157, TB-500, CJC-1295, sermorelin, ipamorelin, injected GHK-Cu) are not approved as drugs in Germany or the EU. This article is not a call for self-medication. Peptide use belongs in the hands of a specialized physician who assesses risks, contraindications and dosing individually. The lab monitoring described here assumes medical supervision.

TL;DR: Before any peptide cycle: CBC, liver, kidney, CRP, glucose, hormones, micronutrients, and IGF-1 for GH peptides. Mid-cycle test at week 4, post-cycle test 1 to 2 weeks after ending. If ALT/AST exceeds 2x upper limit, creatinine rises over 25 percent, or CRP exceeds 10 mg/l, stop the cycle immediately and seek medical evaluation.

Why Lab Monitoring Is Mandatory for Peptides

Peptides intervene in signaling pathways that control growth, regeneration, vascularization and hormonal balance. Most of these substances are unapproved and therefore lack structured long-term human data. That makes individual lab monitoring your most important safety net.

Three reasons not to start without baseline and follow-up values:

1. Spot what was already off. Mildly elevated liver values, latent insulin resistance or low ferritin are common in biohackers, and the peptide gets blamed unfairly when a mid-cycle value looks abnormal.
2. Course-correct early. IGF-1 above 350 ng/ml, rising creatinine or a CRP spike are signals that allow dose adjustment or a stop long before symptoms appear.
3. Prove individual effect. A cycle that “felt good” subjectively but shows no measurable change is expensive and risky. Labs provide evidence that your dose and protocol work for you.

A practical example: You plan a 12-week CJC-1295 cycle. Baseline: IGF-1 at 155 ng/ml, fasting glucose 92 mg/dl. At week 4: IGF-1 at 285 ng/ml, glucose 108 mg/dl. That hits the target corridor — you continue. Without baseline you could not tell if movement is physiological or dose-driven. In Lab2go you see both trajectories side by side and can decide immediately.

Baseline Before the Cycle: 1 to 2 Weeks Prior

The baseline is the reference point for every later measurement. Timing matters: not right after heavy training, not after an infection, fasted in the morning. Women: for hormone measurements, document cycle phase (ideally day 3 to 5 or day 19 to 22).

Baseline Panel Overview

Category	Markers	Purpose
Blood count	RBC, hemoglobin, hematocrit, MCV, WBC with diff, platelets	Anemia, infection, baseline status
Inflammation	hs-CRP, ferritin, optional IL-6	Background inflammation, hidden processes
Liver	ALT, AST, GGT, ALP, bilirubin, albumin	Hepatocyte damage, cholestasis, synthesis
Kidney	Creatinine, eGFR, cystatin C, urea	Filtration capacity
Metabolism	Fasting glucose, fasting insulin, HOMA-IR, HbA1c	Insulin resistance, diabetes risk
Lipids	Total cholesterol, LDL, HDL, triglycerides, Apo B, Lp(a)	Cardiovascular risk
Hormones	Total + free testosterone, SHBG, estradiol, DHEA-S, TSH, fT3, fT4, morning cortisol	Hormonal axis
Micronutrients	25-OH vitamin D, ferritin, B12, folate, zinc, magnesium (whole blood)	Nutrient status
Peptide-specific	IGF-1 (for GH peptides), PSA (men over 45)	Target + screening

For a structured baseline list independent of peptides, read the biomarker baseline checklist. Those markers form the foundation that peptide-specific markers extend.

Why Cystatin C in Addition to Creatinine

Creatinine is muscle-dependent. If you train, supplement creatine or carry a lot of muscle mass, you produce more creatinine — the eGFR falls mathematically without the kidney actually filtering worse. Cystatin C is muscle-independent and delivers the honest picture in athletes. Details in the guide on kidney values.

Mid-Cycle Test at Week 4

After 4 weeks into the cycle, the interim status is decisive. You test reduced but targeted.

Core markers for the mid-cycle test:

• Complete blood count (with differential)
• Liver values: ALT, AST, GGT, bilirubin
• Kidney values: creatinine, eGFR, cystatin C
• hs-CRP
• For GH peptides: IGF-1, fasting glucose, HbA1c
• For GLP-1: lipase, amylase, HbA1c
• For thymosin α1: lymphocyte subsets (CD3, CD4, CD8)

Thresholds that require attention:

Marker	Baseline	Week-4 Check	Action
ALT/AST	below reference	above 2x upper limit	Pause cycle, investigate cause
Creatinine	baseline value	rise over 25 percent	Hydrate, retest in 1 week
hs-CRP	below 1 mg/l	above 10 mg/l	Rule out infection, consider stop
IGF-1	120–180 ng/ml	above 350 ng/ml	Halve dose or stop
Hemoglobin	baseline	drop over 10 percent	Iron status, bleeding source
Fasting glucose	below 100 mg/dl	above 110 mg/dl	Check carbs, GH dose

Small fluctuations are normal. An isolated value just above the reference range with otherwise clean labs is not cause for panic — but it does justify a targeted retest in 7 to 14 days.

Post-Cycle Test: 1 to 2 Weeks After Ending

The post-cycle test repeats the baseline completely. Why wait 1 to 2 weeks? Many peptides have biological after-effects, and acute effects (like a CRP spike from injection site irritation) should have resolved.

Comparison points that matter:

• IGF-1 after GH peptides: expected to return toward baseline. If still above 250 ng/ml after 4 weeks of pause, talk to your physician.
• Fasting glucose and HbA1c: should normalize after GH and GLP-1 peptides.
• Liver and kidney values: no sustained elevation compared to baseline.
• Hormones: testosterone, estradiol, TSH stable or slightly shifted (physiologically possible).

Document the full trajectory in lab2go: baseline, week 4, post-cycle. Only then do you see in your next cycle whether effects are reproducible. For the methodology of long-term tracking, read the guide on long-term biomarker tracking.

Peptide-Specific Monitoring

Not every peptide targets the same systems. This mapping table shows which markers are especially relevant per substance.

Peptide Group	Examples	Primary Markers	Additional Markers
Growth hormone peptides	CJC-1295, sermorelin, ipamorelin, tesamorelin, hexarelin	IGF-1 (target 200–300), fasting glucose, HbA1c	TSH, fT3, fT4, prolactin, cortisol
Healing peptides	BPC-157, TB-500	CBC, CRP, liver, kidney	Age-appropriate cancer screen
Immune modulators	Thymosin α1	CBC with lymphocyte subsets (CD3/CD4/CD8)	Autoimmune panel if at risk
Copper peptides	GHK-Cu (systemic)	Copper, ceruloplasmin, liver values	Zinc (Cu/Zn ratio)
Melanocortins	Melanotan II, PT-141	Blood pressure, CBC	Skin check, ferritin
GLP-1 analogs	Semaglutide, tirzepatide	HbA1c, lipase, amylase, liver	Gallbladder US, thyroid
Sex hormone peptides	Kisspeptin, gonadorelin	Testosterone, LH, FSH, estradiol	Semen analysis if fertility matters

Growth Hormone Peptides: IGF-1 in Focus

CJC-1295, sermorelin, ipamorelin and tesamorelin stimulate endogenous GH production. The biomarker that reflects activity is IGF-1 (insulin-like growth factor 1). IGF-1 shows the average GH activity of the last days and fluctuates less than GH itself.

Target corridor: 200 to 300 ng/ml in middle-aged adults. The upper reference changes with age:

Age	Upper Reference (ng/ml)	Target Under Peptide
25–35	280	220–280
35–45	230	200–260
45–55	200	180–240
55+	180	160–220

Above 350 ng/ml is problematic. Acromegaly-like symptoms (facial/hand/foot enlargement, joint pain, fluid retention) appear with sustained high values. At the same time, insulin resistance risk rises — so always monitor fasting glucose and HbA1c in parallel.

BPC-157 and TB-500

For healing peptides, safety is the priority. CBC, CRP, liver and kidney values must stay clean. Angiogenic action makes age-appropriate cancer screening sensible — especially for men over 45 (PSA) and people with family history. More on the mechanism in the BPC-157 guide.

Thymosin α1: Immune Monitoring

Thymosin α1 modulates the adaptive immune system. Lab monitoring goes beyond a standard CBC. Lymphocyte subsets (CD3, CD4, CD8) show the shift in immune cell populations. For people with autoimmune history, ANA, rheumatoid factor and organ-specific antibodies before start are mandatory. Details in the thymosin α1 guide.

Systemic GHK-Cu

With systemic GHK-Cu use, copper homeostasis and liver are critical. Serum copper and ceruloplasmin before and during the cycle. Monitor zinc in parallel — excess copper displaces zinc. Details in the GHK-Cu guide.

GLP-1 Analogs

Semaglutide and tirzepatide — unlike BPC-157 — are available in approved forms (Ozempic, Wegovy, Mounjaro). Monitoring is standardized: lipase and amylase for pancreatic surveillance, liver values, HbA1c, lipid profile. Rapid weight loss raises gallstone risk — a gallbladder ultrasound before start is useful. Family history of MTC is an absolute contraindication.

Warning Signs: When to Stop the Cycle Immediately

These criteria do not allow discussion. If any of the following shows up, pause the cycle and contact your physician:

• ALT or AST above 2x upper reference. That means ALT above 90 U/L (men) or 68 U/L (women), AST above 70 U/L. More in the guide on liver values.
• Creatinine rise over 25 percent from baseline. Example: baseline 0.9 mg/dl, new 1.15 mg/dl. This is relevant even if the value is still within reference range.
• hs-CRP above 10 mg/l without a clear infection. An acute infection explains the rise — then retest after 2 weeks. If CRP stays high, there is an inflammatory cause that needs investigation.
• Hemoglobin drop over 10 percent. Baseline 14.5 g/dl, new below 13.0 g/dl. Check iron status and bleeding sources (gastrointestinal).
• IGF-1 above 350 ng/ml for GH peptides. Halve the dose or pause.
• Unusual skin lesions. New or growing moles, non-healing wounds, dark discoloration — see a dermatologist within 2 weeks.
• New pain or swelling. Especially abdominal pain (pancreatitis with GLP-1), joint pain (fluid retention with GH) or chest pain (cardiac workup).

For GLP-1 peptides additionally: lipase over 3x upper limit, persistent upper abdominal pain, yellowing of the skin.

Documentation in lab2go

A cycle without documentation is a blind flight. Structure every cycle log by the same schema:

1. Substance and dose. Peptide name, dose per administration, frequency (daily, 5/2, EOD), route (s.c., oral), time of day.
2. Cycle duration. Start date, planned end date, actual end date.
3. Lab values per measurement point. Baseline, mid-cycle, post-cycle. All values in lab2go with date.
4. Subjective effects. Sleep quality, energy, joints, skin, mood, libido — each on a 1 to 10 scale.
5. Events. Infections, new medications, supplement changes, intense training blocks.

This creates a protocol that serves as reference for future cycles. You compare: did I feel better or worse on the last CJC-1295 cycle? Which dose produced the effect without IGF-1 excess? Without this data base, every cycle starts from scratch.

Cost Overview

Lab monitoring costs money — but less than most peptide cycles themselves.

Panel	Scope	Cost per Measurement
Basic	CBC, liver, kidney, CRP, glucose	80–150 euros
Standard	Basic + lipids, HbA1c, hormones (T, SHBG, TSH)	200–350 euros
Extended	Standard + IGF-1, estradiol, cortisol, cystatin C, micronutrients	300–500 euros
Full	Extended + cancer screen, lipase/amylase, lymphocyte subsets	450–600 euros

Three measurement points across a 12-week cycle land realistically at 600 to 1500 euros. Statutory health insurance covers parts only with a medical indication (e.g. suspected GH deficiency, liver disease). Online labs are often cheaper than in-person clinics, but do not include medical interpretation.

Practical Flow: Your First Cycle With Monitoring

Week -2 to -1: Baseline blood draw, fasted in the morning. Full panel including peptide-specific markers. Enter results in lab2go.

Week 0: Cycle start. Document dose, substance and time of day.

Week 4: Mid-cycle test. Core markers + peptide-specific. Compare values. If abnormal: adjust dose or stop — always with medical input.

Week 8 (for long cycles): Optional interim check, especially for GH peptides (IGF-1, glucose).

Week 12: End of cycle.

Week 13 to 14: Post-cycle blood draw. Full panel. Compare with baseline. Final assessment in lab2go.

Week 16 to 20: Pause. After at least 4 weeks of pause, consider the next cycle — again with baseline.

Conclusion: Labs Make Peptides Measurable

Peptides without lab monitoring are an experiment without a control group. If you invest in a substance that lacks full human data, you need individual safety data — and that only comes from your own blood.

Three steps to start:

1. Plan baseline. 1 to 2 weeks before cycle start, full panel per the categories above. Cost: 200 to 500 euros depending on scope.
2. Lock in the mid-cycle test. Put the week-4 appointment in your calendar. Do not postpone.
3. Document everything in lab2go. Substance, dose, lab values, subjective effects — cycle by cycle.

If you are planning your first peptide cycle, start with the peptides beginners guide and the biomarker baseline checklist. For the technical setup of your tracking, check the features of Lab2go or compare the plans and pricing.

This article does not replace medical advice. Peptide use belongs under medical supervision. If lab values deviate, new symptoms appear or uncertainty arises, consult a physician immediately. Self-medication with unapproved substances carries legal and medical risk.